0001062993-23-020714.txt : 20231113
0001062993-23-020714.hdr.sgml : 20231113
20231113190141
ACCESSION NUMBER: 0001062993-23-020714
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231108
FILED AS OF DATE: 20231113
DATE AS OF CHANGE: 20231113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burow Kristina
CENTRAL INDEX KEY: 0001569248
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41802
FILM NUMBER: 231400908
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neumora Therapeutics, Inc.
CENTRAL INDEX KEY: 0001885522
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 844367680
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY, SUITE 200
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (857) 760-0900
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY, SUITE 200
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: RBNC Therapeutics, Inc.
DATE OF NAME CHANGE: 20210929
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2023-11-08
0001885522
Neumora Therapeutics, Inc.
NMRA
0001569248
Burow Kristina
8755 W. HIGGINS ROAD,SUITE 1025
CHICAGO
IL
60631
1
0
1
0
0
Common Stock
2023-11-08
4
P
0
69127
10.78
A
4024719
I
By ARCH Venture Fund XII, L.P.
Common Stock
2023-11-08
4
P
0
23124
11.79
A
4047843
I
By ARCH Venture Fund XII, L.P.
Common Stock
2023-11-09
4
P
0
31079
10.53
A
4078922
I
By ARCH Venture Fund XII, L.P.
Common Stock
2023-11-10
4
P
0
11844
11.37
A
4090766
I
By ARCH Venture Fund XII, L.P.
Common Stock
2023-11-10
4
P
0
5431
11.75
A
4096197
I
By ARCH Venture Fund XII, L.P.
Common Stock
13620
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.4891, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.5007 to $12.00, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.445 to $10.7975, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.62 to $11.61, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.63 to $11.8922, inclusive.
Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023.
Kristina Burow, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact
2023-11-13